Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RHEB | Q15382 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.48 |
| ▸ | RELA | Q04206 | 1/20 | 0.48 |
| ▸ | TNKS | O95271 | 1/20 | 0.46 |
| ▸ | RAF1 | P04049 | 1/20 | 0.45 |
| ▸ | MMP2 | P08253 | 1/20 | 0.45 |
| ▸ | MMP9 | P14780 | 1/20 | 0.45 |
| ▸ | MMP8 | P22894 | 1/20 | 0.45 |
| ▸ | MMP13 | P45452 | 1/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.44 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3084527 | 0.88 | RHEB (0.56) | RHEBALDH1A1KDM4ELMNANPC1 | |
| SCHEMBL3087718 | 0.86 | PARP1 (0.43) | RHEBALDH1A1KDM4EHPGDMMP2 | |
| SCHEMBL3088896 | 0.86 | ALDH1A1 (0.51) | RHEBALDH1A1KDM4ELMNANPC1 | |
| SCHEMBL3103098 | 0.86 | MAPK14 (0.49) | RHEBALDH1A1KDM4ELMNANPC1 | |
| SCHEMBL4909019 | 0.81 | RHEB (0.57) | RHEBALDH1A1KDM4ELMNANPC1 | |
| SCHEMBL3095772 | 0.81 | RHEB (0.51) | RHEBALDH1A1KDM4ELMNANPC1 | |
| SCHEMBL3096393 | 0.81 | RHEB (0.51) | RHEBALDH1A1KDM4ELMNANPC1 | |
| SCHEMBL4937886 | 0.80 | KDM4E (0.55) | RHEBALDH1A1KDM4ELMNANPC1 | |
| SCHEMBL3078427 | 0.77 | LRRK2 (0.48) | SMN1; SMN2PKMHPGD | |
| SCHEMBL3097032 | 0.76 | RHEB (0.66) | RHEBALDH1A1KDM4ELMNANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100234593-A1 | Imidazo[4,5-B]Pyridine-7-Carboxamides 704 | ASTRAZENECA AB (SE) | 2010-09-16 | — | — | US | claimed |
| CN-101679421-A | Novel imidazo [4, 5-b ] pyridine-7-carboxamides 704 | ASTRAZENECA AB | 2010-03-24 | — | — | CN | claimed |
| WO-2008121064-A1 | NEW IMIDAZO[4,5-B]PYRIDINE-6-HALO-7-ARYL/HETEROARYL COMPOUNDS 705 | ASTRAZENECA AB (SE) | 2008-10-09 | — | — | WO | claimed |
| US-20100234593-A1 | Imidazo[4,5-B]Pyridine-7-Carboxamides 704 | ASTRAZENECA AB (SE) | 2010-09-16 | — | — | US | disclosed |
| US-20100234593-A1 | Imidazo[4,5-B]Pyridine-7-Carboxamides 704 | ASTRAZENECA AB (SE) | 2010-09-16 | — | — | US | disclosed |
| US-20100234593-A1 | Imidazo[4,5-B]Pyridine-7-Carboxamides 704 | ASTRAZENECA AB (SE) | 2010-09-16 | — | — | US | disclosed |
| CN-101679421-A | Novel imidazo [4, 5-b ] pyridine-7-carboxamides 704 | ASTRAZENECA AB | 2010-03-24 | — | — | CN | disclosed |
| WO-2008121063-A1 | NEW IMIDAZO[ 4,5-B]PYRIDINE-7-CARBOXAMIDES 704 | ASTRAZENECA AB (SE) | 2008-10-09 | — | — | WO | disclosed |
| WO-2008121064-A1 | NEW IMIDAZO[4,5-B]PYRIDINE-6-HALO-7-ARYL/HETEROARYL COMPOUNDS 705 | ASTRAZENECA AB (SE) | 2008-10-09 | — | — | WO | disclosed |
| WO-2008121064-A1 | NEW IMIDAZO[4,5-B]PYRIDINE-6-HALO-7-ARYL/HETEROARYL COMPOUNDS 705 | ASTRAZENECA AB (SE) | 2008-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234593-A1 | Imidazo[4,5-B]Pyridine-7-Carboxamides 704 | HDAC4, HDAC7, BRD4 | RHEB 3237/4885ALDH1A1 988/4885KDM4E 172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.